_id
69105330ccc777a4e85d550b
Ticker
CORT
Name
Corcept Therapeutics Incorporated
Exchange
NASDAQ
Address
101 Redwood Shores Parkway, Redwood City, CA, United States, 94065
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.corcept.com
Description
Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of hypercortisolism; relacorilant combined with nab-paclitaxel which is in phase III clinical trial to treat platinum-resistant ovarian tumors; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; and for treatment for prostate cancer which is in phase II clinical trial. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; and miricorilant, which is in phase IIb trial for the treatment of metabolic dysfunction-associated steatohepatitis. The company was incorporated in 1998 and is headquartered in Redwood City, California.
Last Close
87.13
Volume
201301
Current Price
87.99
Change
0.9870308734075514
Last Updated
2025-11-29T11:45:42.479Z
Image
data:image/webp;base64,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
Ipo Date
2004-04-14T00:00:00.000Z
Market Cap
8366515200
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.8702424242424243
Sentiment Sources
33
Rating
4.5
Target Price
135.25
Strong Buy
2
Buy
2
Hold
0
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
207638000
Cost Of Revenue
4596000
Gross Profit
203042000
Operating Expenses
192823000
Operating Income
10219000
Interest Expense
-
Pretax Income
15243000
Net Income
19359000
Eps
0.16208273679451435
Dividends Per Share
-
Shares Outstanding
105188217
Income Tax Expense
4425000
EBITDA
15720000
Operating Margin
4.921546152438379
Total Other Income Expense Net
5024000
Cash
125138000
Short Term Investments
296545000
Receivables
73529000
Inventories
12349000
Total Current Assets
541130000
Property Plant Equipment
6870000
Total Assets
823607000
Payables
34446000
Short Term Debt
1050000
Long Term Debt
-
Total Liabilities
191705000
Equity
631902000
Depreciation
477000
Change In Working Capital
3348000
Cash From Operations
54481000
Capital Expenditures
0
Cash From Investing
14645000
Cash From Financing
-46413000
Net Change In Cash
22393000
PE
91.2644
PB
16.631435903035594
ROE
3.063607964526145
ROA
2.350514262263434
FCF
54481000
Fcf Percent
0.2623845346227569
Piotroski FScore
4
Health Score
66
Deep Value Investing Score
5.5
Defensive Investing Score
7.5
Dividend Investing Score
3
Economic Moat Investing Score
7.3
Garp Investing Score
4.5
Growth Investing Score
3.5
Momentum Investing Score
6.5
Net Net Investing Score
4
Quality Investing Score
7
Value Investing Score
4.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
207638000
Quarters > 0 > income Statement > cost Of Revenue
4596000
Quarters > 0 > income Statement > gross Profit
203042000
Quarters > 0 > income Statement > operating Expenses
192823000
Quarters > 0 > income Statement > operating Income
10219000
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
15243000
Quarters > 0 > income Statement > net Income
19359000
Quarters > 0 > income Statement > eps
0.16208273679451435
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
119439000
Quarters > 0 > income Statement > income Tax Expense
4425000
Quarters > 0 > income Statement > EBITDA
15720000
Quarters > 0 > income Statement > operating Margin
4.921546152438379
Quarters > 0 > income Statement > total Other Income Expense Net
5024000
Quarters > 0 > balance Sheet > cash
125138000
Quarters > 0 > balance Sheet > short Term Investments
296545000
Quarters > 0 > balance Sheet > receivables
73529000
Quarters > 0 > balance Sheet > inventories
12349000
Quarters > 0 > balance Sheet > total Current Assets
541130000
Quarters > 0 > balance Sheet > property Plant Equipment
6870000
Quarters > 0 > balance Sheet > total Assets
823607000
Quarters > 0 > balance Sheet > payables
34446000
Quarters > 0 > balance Sheet > short Term Debt
1050000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
191705000
Quarters > 0 > balance Sheet > equity
631902000
Quarters > 0 > cash Flow > net Income
19359000
Quarters > 0 > cash Flow > depreciation
477000
Quarters > 0 > cash Flow > change In Working Capital
3348000
Quarters > 0 > cash Flow > cash From Operations
54481000
Quarters > 0 > cash Flow > capital Expenditures
0
Quarters > 0 > cash Flow > cash From Investing
14645000
Quarters > 0 > cash Flow > cash From Financing
-46413000
Quarters > 0 > cash Flow > net Change In Cash
22393000
Quarters > 0 > ratios > PE
0.16208273679451435
Quarters > 0 > ratios > PB
16.631435903035594
Quarters > 0 > ratios > ROE
3.063607964526145
Quarters > 0 > ratios > ROA
2.350514262263434
Quarters > 0 > ratios > FCF
54481000
Quarters > 0 > ratios > Piotroski FScore
4
Quarters > 0 > ratios > fcf Percent
0.2623845346227569
Quarters > 0 > health Score
66
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
194430000
Quarters > 1 > income Statement > cost Of Revenue
3433000
Quarters > 1 > income Statement > gross Profit
190997000
Quarters > 1 > income Statement > operating Expenses
164322000
Quarters > 1 > income Statement > operating Income
26675000
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
31692000
Quarters > 1 > income Statement > net Income
35149000
Quarters > 1 > income Statement > eps
0.29172926090384693
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
120485000
Quarters > 1 > income Statement > income Tax Expense
-3457000
Quarters > 1 > income Statement > EBITDA
27144000
Quarters > 1 > income Statement > operating Margin
13.719590598158721
Quarters > 1 > income Statement > total Other Income Expense Net
5017000
Quarters > 1 > balance Sheet > cash
102745000
Quarters > 1 > balance Sheet > short Term Investments
239481000
Quarters > 1 > balance Sheet > receivables
68667000
Quarters > 1 > balance Sheet > inventories
12276000
Quarters > 1 > balance Sheet > total Current Assets
443112000
Quarters > 1 > balance Sheet > property Plant Equipment
7312000
Quarters > 1 > balance Sheet > total Assets
801722000
Quarters > 1 > balance Sheet > payables
23525000
Quarters > 1 > balance Sheet > short Term Debt
1016999
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
165929000
Quarters > 1 > balance Sheet > equity
635793000
Quarters > 1 > cash Flow > net Income
35149000
Quarters > 1 > cash Flow > depreciation
469000
Quarters > 1 > cash Flow > change In Working Capital
8374000
Quarters > 1 > cash Flow > cash From Operations
43939000
Quarters > 1 > cash Flow > capital Expenditures
57000
Quarters > 1 > cash Flow > cash From Investing
70127000
Quarters > 1 > cash Flow > cash From Financing
-102934000
Quarters > 1 > cash Flow > net Change In Cash
12926000
Quarters > 1 > ratios > PE
0.29172926090384693
Quarters > 1 > ratios > PB
16.674413134463574
Quarters > 1 > ratios > ROE
5.528371655554559
Quarters > 1 > ratios > ROA
4.384188035254115
Quarters > 1 > ratios > FCF
43882000
Quarters > 1 > ratios > Piotroski FScore
4
Quarters > 1 > ratios > fcf Percent
0.22569562310343055
Quarters > 1 > health Score
70
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
157214000
Quarters > 2 > income Statement > cost Of Revenue
2403000
Quarters > 2 > income Statement > gross Profit
154811000
Quarters > 2 > income Statement > operating Expenses
151395000
Quarters > 2 > income Statement > operating Income
3416000
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
9618000
Quarters > 2 > income Statement > net Income
20288000
Quarters > 2 > income Statement > eps
0.1693220607750023
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
119819000
Quarters > 2 > income Statement > income Tax Expense
-10929000
Quarters > 2 > income Statement > EBITDA
3878000
Quarters > 2 > income Statement > operating Margin
2.172834480389787
Quarters > 2 > income Statement > total Other Income Expense Net
6202000
Quarters > 2 > balance Sheet > cash
89819000
Quarters > 2 > balance Sheet > short Term Investments
232944000
Quarters > 2 > balance Sheet > receivables
84419000
Quarters > 2 > balance Sheet > inventories
14368000
Quarters > 2 > balance Sheet > total Current Assets
438503000
Quarters > 2 > balance Sheet > property Plant Equipment
7690000
Quarters > 2 > balance Sheet > total Assets
846455000
Quarters > 2 > balance Sheet > payables
27947000
Quarters > 2 > balance Sheet > short Term Debt
984000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
163170000
Quarters > 2 > balance Sheet > equity
683285000
Quarters > 2 > cash Flow > net Income
20547000
Quarters > 2 > cash Flow > depreciation
462000
Quarters > 2 > cash Flow > change In Working Capital
-22313000
Quarters > 2 > cash Flow > cash From Operations
5128000
Quarters > 2 > cash Flow > capital Expenditures
104000
Quarters > 2 > cash Flow > cash From Investing
-3171000
Quarters > 2 > cash Flow > cash From Financing
-39803000
Quarters > 2 > cash Flow > net Change In Cash
-37846000
Quarters > 2 > ratios > PE
0.1693220607750023
Quarters > 2 > ratios > PB
15.429687187630345
Quarters > 2 > ratios > ROE
2.9691856253247177
Quarters > 2 > ratios > ROA
2.396819677360285
Quarters > 2 > ratios > FCF
5024000
Quarters > 2 > ratios > Piotroski FScore
3
Quarters > 2 > ratios > fcf Percent
0.0319564415382854
Quarters > 2 > health Score
48
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
181890000
Quarters > 3 > income Statement > cost Of Revenue
2956000
Quarters > 3 > income Statement > gross Profit
178934000
Quarters > 3 > income Statement > operating Expenses
153672000
Quarters > 3 > income Statement > operating Income
25262000
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
31960000
Quarters > 3 > income Statement > net Income
30389000
Quarters > 3 > income Statement > eps
0.25653601668087694
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
118459000
Quarters > 3 > income Statement > income Tax Expense
1214000
Quarters > 3 > income Statement > EBITDA
25722000
Quarters > 3 > income Statement > operating Margin
13.888613997471
Quarters > 3 > income Statement > total Other Income Expense Net
6698000
Quarters > 3 > balance Sheet > cash
127665000
Quarters > 3 > balance Sheet > short Term Investments
255669000
Quarters > 3 > balance Sheet > receivables
58076000
Quarters > 3 > balance Sheet > inventories
12412000
Quarters > 3 > balance Sheet > total Current Assets
471602000
Quarters > 3 > balance Sheet > property Plant Equipment
8013000
Quarters > 3 > balance Sheet > total Assets
840553000
Quarters > 3 > balance Sheet > payables
15376000
Quarters > 3 > balance Sheet > short Term Debt
829000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
160964000
Quarters > 3 > balance Sheet > equity
679589000
Quarters > 3 > cash Flow > net Income
30389000
Quarters > 3 > cash Flow > depreciation
460000
Quarters > 3 > cash Flow > change In Working Capital
17347000
Quarters > 3 > cash Flow > cash From Operations
59300000
Quarters > 3 > cash Flow > capital Expenditures
121000
Quarters > 3 > cash Flow > cash From Investing
-64360000
Quarters > 3 > cash Flow > cash From Financing
-4564000
Quarters > 3 > cash Flow > net Change In Cash
-9624000
Quarters > 3 > ratios > PE
0.25653601668087694
Quarters > 3 > ratios > PB
15.337516366509757
Quarters > 3 > ratios > ROE
4.471673320197944
Quarters > 3 > ratios > ROA
3.6153579845649237
Quarters > 3 > ratios > FCF
59179000
Quarters > 3 > ratios > Piotroski FScore
4
Quarters > 3 > ratios > fcf Percent
0.3253559843861675
Quarters > 3 > health Score
68
Valuation > metrics > PE
91.2644
Valuation > metrics > PB
16.631435903035594
Valuation > final Score
1
Valuation > verdict
359.7% Overvalued
Profitability > metrics > ROE
3.063607964526145
Profitability > metrics > ROA
3.5775137212869366
Profitability > metrics > Net Margin
0.09323437906356255
Profitability > final Score
31
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.3033777389531921
Risk > metrics > Interest Coverage
21.42348008385744
Risk > final Score
100
Risk > verdict
Low
Liquidity > metrics > Current Ratio
15.24481631733153
Liquidity > metrics > Quick Ratio
14.896917962587334
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
40
Prev Valuations > 1
40
Prev Valuations > 2
40
Prev Profitabilities > 0
62
Prev Profitabilities > 1
39
Prev Profitabilities > 2
53
Prev Risks > 0
83
Prev Risks > 1
62
Prev Risks > 2
76
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2025-12-14T00:21:33.882Z
Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of hypercortisolism; relacorilant combined with nab-paclitaxel which is in phase III clinical trial to treat platinum-resistant ovarian tumors; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; and for treatment for prostate cancer which is in phase II clinical trial. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; and miricorilant, which is in phase IIb trial for the treatment of metabolic dysfunction-associated steatohepatitis. The company was incorporated in 1998 and is headquartered in Redwood City, California.
Stock Price
$ 0.00
0% increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/ACoppell Advisory Solutions LLC Has $2.32 Million Stake in Corcept Therapeutics Incorporated $CORT MarketBeat
Read more →Assessing Corcept Therapeutics (CORT) Valuation After Bullish Analyst Views on Korlym and Relacorilant’s PDUFA Milestone simplywall.st
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
STRONG BUY
Target Price:
$135.25
Analyst Picks
Strong Buy
2
Buy
2
Hold
0
Sell
0
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Earnings Ratio (P/E)
-
Very Low
Low ≥ 50
High ≤ 10
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very High
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 75.72% of the total shares of Corcept Therapeutics Incorporated
1.
BlackRock Inc(11.892%)
since
2025/06/30
2.
Vanguard Group Inc(9.1871%)
since
2025/06/30
3.
Ingalls & Snyder LLC(7.3292%)
since
2025/06/30
4.
Renaissance Technologies Corp(5.9469%)
since
2025/06/30
5.
iShares Core S&P Small-Cap ETF(5.3262%)
since
2025/08/31
6.
Parallel Advisors, LLC(3.6738%)
since
2025/06/30
7.
State Street Corp(2.8163%)
since
2025/06/30
8.
Vanguard Total Stock Mkt Idx Inv(2.6862%)
since
2025/07/31
9.
Vanguard Small Cap Index(2.0771%)
since
2025/07/31
10.
Dimensional Fund Advisors, Inc.(1.9792%)
since
2025/06/30
11.
Geode Capital Management, LLC(1.818%)
since
2025/06/30
12.
Morgan Stanley - Brokerage Accounts(1.5318%)
since
2025/06/30
13.
FMR Inc(1.2878%)
since
2025/06/30
14.
Vanguard Small Cap Growth Index Inv(1.1701%)
since
2025/07/31
15.
ClearBridge Advisors, LLC(1.1084%)
since
2025/06/30
16.
Amvescap Plc.(0.9791%)
since
2025/06/30
17.
Vanguard Institutional Extnd Mkt Idx Tr(0.9629%)
since
2025/07/31
18.
NORGES BANK(0.9315%)
since
2025/06/30
19.
SPDR® Portfolio S&P 600™ Sm Cap ETF(0.792%)
since
2025/08/29
20.
TD Asset Management Inc(0.7781%)
since
2025/06/30
21.
Charles Schwab Investment Management Inc(0.7729%)
since
2025/06/30
22.
iShares S&P Small-Cap 600 Growth ETF(0.7707%)
since
2025/08/31
23.
Arrowstreet Capital Limited Partnership(0.7486%)
since
2025/06/30
24.
TD Global Investment Solutions – TD Epoch(0.7264%)
since
2025/06/30
25.
HPM Partners LLC(0.7085%)
since
2025/06/30
26.
Fidelity Select Biotechnology(0.6843%)
since
2025/07/31
27.
D. E. Shaw & Co LP(0.6388%)
since
2025/06/30
28.
Invesco S&P SmallCap Momentum ETF(0.6377%)
since
2025/08/29
29.
Northern Trust Corp(0.619%)
since
2025/06/30
30.
iShares Russell Mid-Cap Growth ETF(0.592%)
since
2025/08/31
31.
Vanguard Tax-Managed Small Cap Adm(0.5844%)
since
2025/07/31
32.
DFA US Small Cap I(0.5262%)
since
2025/07/31
33.
Fidelity Extended Market Index(0.4826%)
since
2025/07/31
34.
ClearBridge Value(0.4745%)
since
2025/07/31
35.
ClearBridge Value C(0.4745%)
since
2025/07/31
36.
First Trust NYSE Arca Biotech ETF(0.4496%)
since
2025/08/28
37.
SPDR® S&P 600 Small Cap Growth ETF(0.4369%)
since
2025/08/31
38.
Schwab US Small-Cap ETFâ„¢(0.4256%)
since
2025/08/30
39.
Principal SmallCap S&P 600 Idx SP(0.3535%)
since
2025/07/31
40.
iShares Russell 1000 Growth ETF(0.3349%)
since
2025/08/31
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.